IGM Biosciences, Inc. (IGMS)

IGM Biosciences, Inc. (IGMS) came out with quarterly earnings of $1.58 per share, beating the Zacks Consensus Estimate of a loss of $0.3 per share. This compares to a loss of $0.79 per share a year ago.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of IGM Biosciences, Inc. (NASDAQ: IGMS) to Concentra Biosciences, LLC is fair to IGM shareholders. Under the terms of the proposed transaction, IGM shareholders would receive $1.247 in cash per share, plus one non-tradeable contingent value right, representing the right to receive additional proceeds under certain circumstances and conditions. Halper Sadeh encourages IGM shareholders to c.

MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common stock (“Common Stock”), plus one non-tradeable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of IGM Biosciences in excess of $82.0 million; and (ii) 80% of any net proceeds received within one year following closing from any disposition of certain of IGM Biosciences' product candidates and intellectual property that occurs within one year following closing, each pursuant to a contingent value rights agreement (the “CVR Agreement”).

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.83 per share a year ago.

IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IGM Biosciences (IGMS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

NEW YORK, NY / ACCESS Newswire / February 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ: IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK, NY / ACCESS Newswire / January 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of IGM Biosciences, Inc. ("IGM Biosciences, Inc.") (NASDAQ:IGMS) concerning possible violations of federal securities laws. IGM issued a press release on January 9, 2025, "announc[ing] a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases.

NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of IGM Biosciences, Inc. ("IGM" or the "Company") (NASDAQ:IGMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Stifel downgraded IGM Biosciences to Hold from Buy with a price target of $2.50, down from $27. Th firm cites the company's "surprising decision" to discontinue all further development of its autoimmune and inflammatory disease applications for the downgrade. The strategic pivot will trigger the evaluation of both internal and external/ alternatives and an over 70% workforce reduction, the analyst tells investors in a research note.

Morgan Stanley analyst Michael Ulz downgraded IGM Biosciences to Underweight from Equal Weight with a price target of $2, down from $12. The company announced discontinuation of its autoimmune programs, a 73% workforce reduction and plans to evaluate strategic alternatives, the analyst tells investors in a research note. The firm cites near-term uncertainty related to the future of IGM for the downgrade.